Cardiovascular Benefits Seen With as Few as 2,600 Steps Daily
By Lori Solomon HealthDay Reporter
WEDNESDAY, Dec. 6, 2023 -- Cardiovascular disease (CVD) benefits can be seen from as few as about 2,600 steps per day, according to a review recently published in the Journal of the American College of Cardiology.
Niels A. Stens, from Radboud University Medical Center in Nijmegen, Netherlands, and colleagues conducted a meta-analysis to quantify dose-response associations between objectively measured step count metrics in the general population. The analysis included 111,309 individuals from 12 studies.
The researchers found significant risk reductions with 2,517 steps/day for all-cause mortality (adjusted hazard ratio [aHR], 0.92) and 2,735 steps/day for incident CVD (aHR, 0.89) versus 2,000 steps/day (reference). There was a nonlinear risk reduction seen for additional steps and risk for all-cause mortality and incident CVD with an optimal dose at 8,763 (aHR, 0.40) and 7,126 steps/day (aHR, 0.49), respectively. There was an independent relationship observed for increments from a low to an intermediate or a high cadence and risk reductions of all-cause mortality. There was no dose-response association seen with sex. After stratification for assessment device and wear location, the investigators found pronounced risk reductions for hip-worn accelerometers versus pedometers and wrist-worn accelerometers.
"These findings can extend contemporary physical activity prescriptions given the easy-to-understand concept of step count," the authors write.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted December 2023
Read this next
Semaglutide Cuts Risk for Kidney Outcomes, Death in CKD With T2DM
FRIDAY, May 31, 2024 -- For patients with type 2 diabetes and chronic kidney disease, semaglutide reduces the risk for clinically important kidney outcomes and death from...
DNA Methylation-Based Epigenetic Age Mediates Link Between LE8 Score, CVD
WEDNESDAY, May 29, 2024 -- The associations between Life's Essential 8 (LE8) and cardiovascular health are mediated by DNA methylation-based epigenetic age, according to a study...
Semaglutide Boosts Kidney Outcomes With Obesity + Cardiovascular Disease
TUESDAY, May 28, 2024 -- Once-weekly subcutaneous semaglutide shows a benefit for kidney outcomes in people with overweight or obesity and established cardiovascular disease...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.